Royal Bank of Canada’s Fidelity Disruptive Medicine ETF FMED Stock Holding History

Royal Bank of Canada’s Portfolio FMED Stock Details FMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2K	Buy	+80	New	+$2.08K	﹤0.01%	6694

Other funds holding FMED

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vise Technologies New York $5.09B AUM 22.62% 1-Year Est. Return

BXM Wealth Englewood, Colorado $184M AUM 36.28% 1-Year Est. Return

GJIA

Glass Jacobson Investment Advisors Owings Mills, Maryland $321M AUM 20.69% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

GEA

Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Royal Bank of Canada's FMED Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Fidelity Disruptive Medicine ETF (FMED) in Q1 2026: 80 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #6694 among its holdings.

11 funds tracked by Wall St. Rank hold FMED as of Q1 2026.

Royal Bank of Canada held 80 shares of Fidelity Disruptive Medicine ETF worth $2K as of Q1 2026.
Fidelity Disruptive Medicine ETF was a new Royal Bank of Canada position in Q1 2026.
Fidelity Disruptive Medicine ETF made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6694 holding.
11 funds tracked by Wall St. Rank held Fidelity Disruptive Medicine ETF as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.